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The life expectancy of humans has markedly increased within the last 100 years. As age is the main risk factor for Alzheimer´s disease (AD), the number of patients suffering from AD, and mixed forms of dementia will increase within the next 50 years. It is expected that there will be about 80 million AD patients worldwide in 2050.
The establishment of reliable diagnostic surrogate markers for AD and measures to monitor disease progression is essential in order to evaluate novel treatmens to counteract and/or delay symptoms in AD and to allow initiation of therapeutic interventions as early as possible. A valid and easily accessible diagnostic procedure should be the basis for the treatment.
Diagnosis of Alzheimer´s disease and other forms of dementia
AD is morphologically characterized by extracellular beta-amyloid plaque deposition, intraneuronal tau pathology, neuronal cell death, vascular dysfunction and inflammatory processes. Diagnosis requires both clinical assessment of the disease and post mortem detection of beta-amyloid plaques and tau-pathology. A probable diagnosis of AD can be established with a confidence of >90%, based on clinical criteria, including medical history, physical examination, laboratory tests, neuroimaging and neuropsychological evaluation. Accurate, early diagnosis of AD is still difficult because early symptoms of the disease are shared by a variety of disorders, reflecting common neuropathological features. The diagnosis of mixed forms of dementia, such as vascular dementia, frontotemporal lobe dementia or Lewy body dementia, is even more difficult.
The search for biomarkers becomes extremely important, due the large expected increase in dementia and AD patients within the next 50 years. It will be necessary to find "biomarkers of aging" and "biomarkers of disease". While a "biomarker of aging" may allow to follow up individuals over several years, a "biomarker of disease" will directly reflect the stage of the disease process (for details on diagnosis see Sprott as well as Cedazo-Minguez and Bengt Winblad; both this special issue of EXG). Briefly, we need to distinguish between biomarkers (1) that add to diagnostic certainty in the setting of a clinical evaluation, (2) those that can be used in lieu of a clinical evaluation, and (3) those that can be used to track disease progression at a specific stage. Although the same biomarker could in theory be used in all these settings, most do not perform evenly across them. In addition, some biomarkers are more reasonably thought about as "risk factors" rather than "true disease" markers. In order for a diagnostic biomarker to be useful, certain criteria need to be met ).
(1) The biomarker should reflect some basic pathophysiological processes, and detect a fundamental feature of the disease with high sensitivity and specificity.
(2) The biomarker should be specific for the disease compared with related disorders. (3) The biomarker should not reflect symptomatology of disorder. (4) The biomarker can be measured repeatedly over time and should be reproducible. (5) The biomarker should be measured in noninvasive easy-to-perform tests. (6) The biomarker should not cause harm to the individual being assessed. (7) The biomarker should be reliable in many testing environments/labs. (8) Validation by pathological diagnosis as gold standard should verify the set up of a biomarker in a specific disease. This mini-review (in concert with the other reviews in this special issue) will
give an overview on the measurement of growth factors and cytokines/chemokines in CSF and blood. It will be shown, that all mentioned factors show a very high heterogenity between the disease groups, and so far none of these biomarkers will meet all criteria for being a good biomarker.
Growth factors in Alzheimers disease
One characteristic feature of AD pathology is death of basal forebrain cholinergic neurons and vascular damage. Nerve growth factor (NGF) is the most potent growth factor able to counteract cell death of cholinergic neurons in vitro and in vivo (Thoenen and Barde 1980; Levi-Montalcini 1987) . While NGF dysfunction has been suggested in the development of AD, NGF knockout mice have not shown clear cognitive deficits. Nevertheless, NGF has been considered a candidate for treating AD and purified NGF was infused in some AD patients (Olson et al. 1992 ). And recently genetically engineered skin cells secreting NGF were transplanted into the nBM of Alzheimer patients by Tuszynski and colleagues (2005) . Interestingly, NGF is up-regulated in brains (Fahnestock et al. 2001) and CSF of AD patients, while the high-affinity NGF receptor trkA is down-regulated (Mufson et al. 2004 ). Furthermore, vascular endothelial growth factor (VEGF) is increased (Fukumura et al. 2001; Tarkowski et al. 2002) , resulting in enhanced microvascular density in developing AD. Other growth factors may also contribute to AD pathology and/or be dysregulated. Platelet-derived growth factor (PDGF) has been found to upregulate amyloid-precursor-protein in hippocampus by inducing secretases (Gianni et al. 2003; Zambrano et al. 2004; Lim et al. 2007 ). Insulin-like growth factor-I (IGF-I) regulates beta-amyloid levels and displays protective effects against beta-amyloid toxicity (Carro et al. 2002; Aguado-Llera et al. 2005) . Fibroblast growth factor-2 (FGF-2) shares binding sites with beta-amyloid fibrils on heparan sulfate from cerebral cortex (Lindahl et al. 1999 ) and plays a role in beta-amyloid toxicity (Cantara et al. 2005) . Finally, members of the transforming growth factor-β (TGF-β) family interact with beta-amyloid, contributing to its toxicity or constituting a risk for cerebral beta-amyloid angiopathy (Hashimoto et al. 2005 and .
Inflammation and Alzheimer's disease
Inflammation may constitute an important trigger of neurodegeneration during aging ("Inflammaging") (Franceschi et al. 2001 ) and anti-inflammatory drugs may delay AD (Perry et al. 1995; Moore and O'Banion 2002) . Chronic release of pro-inflammatory cytokines, such as interleukin-1β or tumor necrosis factor-α suggests roles in inflammation, pathology, and neuronal dysfunction associated with AD (Perry et al. 1995; Grammas and Ovase 2002) . These inflammatory processes include activation of microglia and subsequent neuroinflammatory processes (Gonzalez-Scarano and Baltuch 1999). However, it is not clear if inflammation is merely a possibly aggravating result of beta-amyloid dysregulation (Moore and O'Banion 2002) or a primary cause of AD. Perivascular small vessel inflammation is a another kehy feaure of AD, and it is well known that endothelial cells respond strongly to inflammatory stimuli (Moser, et al. 2004) , especially involving production of reactive oxygen species (Iadecola 2004) .
A. GROWTH FACTORS
Growth factors are proteins, which support the survival of cells of the central and peripheral nervous system, play a role in the development of the brain, stimulate axonal growth and regulate the growth of different kinds of cells in the brain and periphery. In many cases the same growth factor and corresponding receptor signaling system may thus serve a number of different functions in the body, Nerve growth factor (NGF) is the most potent factor providing trophic support of cholinergic neurons in the basal forebrain. These cholinergic neurons degenerate early in AD, possibly due to compromised retrograde transport of NGF to the cell bodies of origin in the basal nucleus of Meynert and septum. NGF has been found to be increased in CSF of AD patients (Table 1A ; Blasko et al., 2006; Marksteiner et al., 2008) . Interestingly, the increase of NGF was specific for AD compared to healthy controls and was dependent on the extent of neurodegeneration as expressed by the phospho-tau181/beta-amyloid ratio (1-42) (Blasko et al., 2006) .
Although NGF data alone did not reveal a significant difference, the comparison of NGF in AD patients having a phospho-tau181/beta-amyloid ratio >10 with healthy control subjects (ratio <6) revealed a significant difference (Blasko et al., 2006) . This might suggest that NGF accumulates in neurodegeneration only at a certain stage of the disease.
Several other growth factors have been measured in CSF or plasma, however, the data are very divergent between the different groups (Table 1A) .
• Hepatocyte growth factor (HGF) is a paracrine cellular growth, motility and morphogenic factor and plays a major role in embryonic organ development, in adult organ regeneration and in wound healing.
• Vascular endothelial growth factor (VEGF) is an important growth factor, regulating angiogenesis in the nervous system.
• Brain-derived neurotrophic factor (BDNF; Barde, 1990) belongs to the family of neurotrophins. It serves very general plastic functions in the adult brain and is strictly upregulated in response to locally increased neuronal activity (Galloway et al., 2008) . Of note, it has been reported that women have higher plasma BDNF levels than men, and that decreased plasma BDNF levels have been suggested to correlate with impaired memory and general cognitive function in aging women but not men (Komulainen et al., 2008 ).
• Glial cell line-derived neurotrophic factor (GDNF) stimulates the survival of several neurons, such as e.g. dopaminergic neurons and motorneurons.
• Fibroblast growth factor-2 (FGF-2, bFGF) belongs to a family of heparinbinding growth factors involved in angiogenesis, wound healing, and embryonic development.
• Transforming growth factor-beta-1 (TGFß-1) plays a role in cellular proliferation and differentiation of a broad range of cells
• Insulin-like growth factor (IGFs) are polypeptides with a marked sequence homology to insulin, playing an important role in cell-cell communication.
Insulin-like growth factor binding protein-6 (IGFBP-6) controls the distribution, function and activity of insulin-like growth factors.
• Epidermal growth factor (EGF) stimulates the proliferation of various epidermal and epithelial cells, inhibits gastric acid secretion and is involved in wound healing.
• Angiopoietin (ANG-2) binds to the endothelial cell specific receptor Tie2 and promotes angiogenesis, sprouting and tube formation and the formation of new blood vessels.
• Platelet-derived growth factor-BB (PDGF-BB) is mitogenic for cells of mesenchymal origin.
• Progranulin is a glycoprotein growth factor involved in the regulation of multiple processes including tumorigenesis, wound repair, development and inflammation.
In summary, consensus is lacking regarding possible changes of the levels of several different growth factor in CSF and plasma in AD. However, NGF levels in CSF seem to be consistently increased in at least certain stages of AD. The consistency of NGF changes adds weight to a role of NGF in AD pathology, particularly when compared to the variable results seen with most other studied growth factors.
B: CYTOKINES AND CHEMOKINES
Cytokines comprise a large diverse family of proteins, peptides or glycoproteins that are used extensively in cellular communication. Historically, the term cytokine was 
Cytokines
Different cytokines have been measured in CSF, plasma or serum (see Table 1B ), such as interleukin-1α and -1ß, interleukin-6 (IL-6), -10 (IL-10), -11 (IL-11), -18 (IL-18) and tumor-necrosis factor alpha (TNF-α, or TNFSF2) or macrophage migration inhibitory factor (MIF). As shown in Table 1B , the measurements are very divergent between the different groups. However, the combination of several chemokines in plasma (e.g. MIP1δ, MIP4 and RANTES; ) may allow to diagnose AD and MCI (see Table 2 ).
Colony-stimulating factors (CoSfF)
Three members belong to the CoSF and have been measured in CSF and plasma (table 1B):
• Granulocyte colony-stimulating factor (G-CSF, or CSF-3) stimulates the bone marrow to produce granulocytes and stem cells and stimulates survival, proliferation, differentiation and function of mature and neutrophil precursors and white blood cells.
• Macrophage colony stimulating factor (M-CSF, CSF-1) regulates proliferation, differentiation and survival of blood monocytes, tissue macrophages and progenitor cells.
• Interleukin-3 (IL-3 or multipotential colony-cstimulating factor, Multi-CSF) is a hematopoietic growth factor that promotes the survival, differentiation and proliferation of megakaryocyte, granulocyte-macrophage, erythroid, eosinophil, basophil and mast cell progenitors and enhances thrombopoiesis, phagocytosis and cellular cytotoxicity and plays a role in immune defense.
Chemokines
Several chemokines have been measured in CSF or plasma, however, measurements are very divergent between the different groups (Table 1B) 
Culture of PBMCs and stimulated release
To increase the specificity and sensitivity for biomarker search, isolated blood cells can be used to explore differential release of cytokines in AD compared to controls.
The stimulation of cultured of peripheral blood mononuclear cells (PBMC) has been performed, and especially lipopolysaccharide (LPS) or phytohaemagglutinin (PHA) or also beta-amyloid seem to be very potent. In LPS stimulated PBMCs enhanced release of different cytokines (e.g. IL-2, TNF-α) has been reported in AD patients (Tan et al., 2007; Bergman et al., 2002; Kassner et al., 2008; Guerreiro et al., 2007; Kaplin et al., 2008) , a decrease of IL-1ß and IL-10 in severely demented patients (Sala et al., 2003; Bergman et al., 2002) , while no effect on IL-6 release was found (Magaki et al., 2006) . In PHA-stimulated cultures of PBMC from patients with MCI a markedly enhanced secretion of IL-6 and a less pronounced enhanced secretion of IL-10 and IL-8, but not of TNFα or IL-1ß, was found (Magaki et al., 2006) . A significant decrease in IL-10 production was found in PBMCs after stimulation with beta-amyloid (Speciale et al., 2007) .
To further explore differential release of cytokines/chemokines/growth factors from PBCMs we isolated in our lab PBMCs from 9 controls, 37 AD, 20 MCI and 11 depressive patients (Table 3) . After stimulation with 4 µg/ml phytohemagglutinin-L (PHA) for 24hr in culture, the levels of biomarkers (interleukins-1α, -3, -11, EGF, G-CSF and MCP-3) were measured in the supernatants by Searchlight mutiplex ELISA or commercial single ELISA (IL-6, BioLegend). Statistical analysis was performed by one way ANOVA with a subsequent Dunnet posthoc test where p<0.05 was significant. Our novel data show that no changes were observed for IL-1α, IL-6, G-CSF and MCP-3 release. However, IL-3 and EGF release were significantly enhanced in MCI but not in the other groups, while IL-11 was significantly decreased in MCI but not in other groups (Table 3) . When calculating the ratio EGF/IL-11 MCI patients could be differentiated from the other groups with high significance (Table 3 ). Our data suggest that the PHA-induced release of EGF and IL-11 from PBMCs may allow to diagnose MCI with high significance.
Summary
In summary, CSF and plasma levels of cytokines and chemokines are very heterogenous in different studies, and changes point to inflammatory reactions in AD.
The striking differences between published studies may partly be due to true variations during the cource of AD, for instance with respect to inflammatory and immune events. Needless to say, other explanations, including methodological differences between groups are also possible. Thus the mean levels of an individual biomarker may vary between serum, EDTA-plasma, citrate plasma and heparin plasma by a factor 20. Different commercial ELISA systems may led to different levels of the biomarkers, depending on the sensitivity and specificity of the used
antibodies. An antibody may detect full length forms or spliced forms or precursor forms. Moreover, some biomarkers may show enhanced binding capacities to plasma/serum proteins, and only a pre-treatment may release the soluble forms. The stability of the biomarkers may vary and freezing and thawing may influence the biochemical biomarker properties. Platelets serve as one storage compartment for several of the measured proteins and differences in platelet stability or perturbation may cause markedly different results. Finally, the ethnicity of patients may have an effect on protein levels as well. Thus, in summary, controlled standardized procedures to measure biomarkers in blood must be established to in order to better compare data from different centers.While more studies are needed to clarify these issues, a combined pattern of several cytokines/chemokines and/or their ratios may become of value in the diagnosis of AD and MCI using blood samples.
CONCLUSIONS
The expression levels of growth factors and cytokines/chemokines in CSF and blood of AD patients are very heterogenous, indicating pathological diversity of AD. In CSF only NGF seems to be sigificantly enhanced, probably reflecting reactions to the ongoing neurodegenerative processes in AD. Inflammatory cytokines and chemokines are differentially regulated, pointing to inflammatory events in AD. At present, no single growth factor or cytokine stands out as a useful biomarker for diagnosing AD or MCI. However, the combined "patients profile signature" of selected growth factors (e.g. EGF) and cytokines/chemokines (e.g. IL-11, RANTES, MIP-1δ δ δ δ, MIP4) may provide a diagnostic tool with high selectively and specificity in AD and MCI by the use of blood samples.
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